Stocks · News reference

Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13

Sep 16, 2026, 5:31 PMBenzinga Newsdesk

Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $12 to $13.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 16, 2026, 11:01 AMBenzinga Newsdesk
Viatris Secures Japan Approval For WAKIX In Treating Excessive Daytime Sleepiness Linked To Sleep Apnea And Narcolepsy
Approval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in JapanPITTSBURGH, Sept. 16, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today
VTRS
BenzingaSep 9, 2026, 3:43 PMBenzinga Newsdesk
Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20
VTRS
BenzingaSep 8, 2026, 12:50 PMBenzinga Newsdesk
Argus Research Maintains Buy on Viatris, Raises Price Target to $20
Argus Research analyst Jasper Hellweg maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $15 to $20.
VTRS